Abstract
Background: Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission. Methods: A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000–2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates of all-age 2000–2018 onchocerciasis infection prevalence at the 5 × 5-km resolution as well as aggregations to the national level, along with corresponding estimates of the uncertainty in these predictions. Results: As of 2018, the prevalence of onchocerciasis infection continues to be concentrated across central and western Africa, with the highest mean estimates at the national level in Ghana (12.2%, 95% uncertainty interval [UI] 5.0–22.7). Mean estimates exceed 5% infection prevalence at the national level for Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Guinea-Bissau, Sierra Leone, and South Sudan. Conclusions: Our analysis suggests that onchocerciasis infection has declined over the last two decades throughout western and central Africa. Focal areas of Angola, Cameroon, the Democratic Republic of the Congo, Ethiopia, Ghana, Guinea, Mali, Nigeria, South Sudan, and Uganda continue to have mean microfiladermia prevalence estimates exceeding 25%. At and above this level, the continuation or initiation of mass drug administration with ivermectin is supported. If national programs aim to eliminate onchocerciasis infection, additional surveillance or supervision of areas of predicted high prevalence would be warranted to ensure sufficiently high coverage of program interventions.
Original language | English |
---|---|
Article number | 293 |
Number of pages | 12 |
Journal | BMC Medicine |
Volume | 20 |
Issue number | 1 |
DOIs | |
Publication status | Published - 7 Sept 2022 |
Keywords
- Geospatial model
- Neglected tropical diseases
- Onchocerciasis
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: BMC Medicine, Vol. 20, No. 1, 293, 07.09.2022.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - The prevalence of onchocerciasis in Africa and Yemen, 2000–2018
T2 - a geospatial analysis
AU - Schmidt, Chris A.
AU - Cromwell, Elizabeth A.
AU - Hill, Elex
AU - Donkers, Katie M.
AU - Schipp, Megan F.
AU - Johnson, Kimberly B.
AU - Pigott, David M.
AU - Abbas, Jaffar
AU - Adekanmbi, Victor
AU - Adetokunboh, Olatunji O.
AU - Ahmed, Muktar Beshir
AU - Alanezi, Fahad Mashhour
AU - Alanzi, Turki M.
AU - Alipour, Vahid
AU - Andrei, Catalina Liliana
AU - Andrei, Tudorel
AU - Anvari, Davood
AU - Appiah, Seth Christopher Yaw
AU - Aqeel, Muhammad
AU - Arabloo, Jalal
AU - Jafarabadi, Mohammad Asghari
AU - Ausloos, Marcel
AU - Baig, Atif Amin
AU - Banach, Maciej
AU - Bärnighausen, Till Winfried
AU - Bhattacharyya, Krittika
AU - Bhutta, Zulfiqar A.
AU - Bijani, Ali
AU - Brady, Oliver J.
AU - Bragazzi, Nicola Luigi
AU - Butt, Zahid A.
AU - Carvalho, Felix
AU - Chattu, Vijay Kumar
AU - Dahlawi, Saad M.A.
AU - Damiani, Giovanni
AU - Demeke, Feleke Mekonnen
AU - Deribe, Kebede
AU - Dharmaratne, Samath Dhamminda
AU - Diaz, Daniel
AU - Didarloo, Alireza
AU - Earl, Lucas
AU - Zaki, Maysaa El Sayed
AU - El Tantawi, Maha
AU - Fattahi, Nazir
AU - Fernandes, Eduarda
AU - Foigt, Nataliya A.
AU - Foroutan, Masoud
AU - Franklin, Richard Charles
AU - Guo, Yuming
AU - Haj-Mirzaian, Arvin
AU - Hamidi, Samer
AU - Hassankhani, Hadi
AU - Herteliu, Claudiu
AU - Higazi, Tarig B.
AU - Hosseini, Mostafa
AU - Hosseinzadeh, Mehdi
AU - Househ, Mowafa
AU - Ilesanmi, Olayinka Stephen
AU - Ilic, Irena M.
AU - Ilic, Milena D.
AU - Irvani, Seyed Sina Naghibi
AU - Jha, Ravi Prakash
AU - Ji, John S.
AU - Jonas, Jost B.
AU - Jozwiak, Jacek Jerzy
AU - Kalankesh, Leila R.
AU - Kamyari, Naser
AU - Matin, Behzad Karami
AU - Karimi, Salah Eddin
AU - Kayode, Gbenga A.
AU - Karyani, Ali Kazemi
AU - Khan, Ejaz Ahmad
AU - Khan, Md Nuruzzaman
AU - Khatab, Khaled
AU - Khater, Mona M.
AU - Kianipour, Neda
AU - Kim, Yun Jin
AU - Kosen, Soewarta
AU - Kusuma, Dian
AU - La Vecchia, Carlo
AU - Lansingh, Van Charles
AU - Lee, Paul H.
AU - Li, Shanshan
AU - Maleki, Shokofeh
AU - Mansournia, Mohammad Ali
AU - Martins-Melo, Francisco Rogerlândio
AU - McAlinden, Colm
AU - Mendoza, Walter
AU - Mestrovic, Tomislav
AU - Moghadaszadeh, Masoud
AU - Mohammadian-Hafshejani, Abdollah
AU - Mohammadi, Seyyede Momeneh
AU - Mohammed, Shafiu
AU - Moradzadeh, Rahmatollah
AU - Moraga, Paula
AU - Naderi, Mehdi
AU - Nagarajan, Ahamarshan Jayaraman
AU - Negoi, Ionut
AU - Nguyen, Cuong Tat
AU - Nguyen, Huong Lan Thi
AU - Oancea, Bogdan
AU - Olagunju, Andrew T.
AU - Bali, Ahmed Omar
AU - Onwujekwe, Obinna E.
AU - Pana, Adrian
AU - Rahimi-Movaghar, Vafa
AU - Ramezanzadeh, Kiana
AU - Rawaf, David Laith
AU - Rawaf, Salman
AU - Rawassizadeh, Reza
AU - Rezapour, Aziz
AU - Ribeiro, Ana Isabel
AU - Samy, Abdallah M.
AU - Shaikh, Masood Ali
AU - Sharafi, Kiomars
AU - Sheikh, Aziz
AU - Singh, Jasvinder A.
AU - Skiadaresi, Eirini
AU - Soltani, Shahin
AU - Stolk, Wilma A.
AU - Sufiyan, Mu’awiyyah Babale
AU - Thomson, Alan J.
AU - Tran, Bach Xuan
AU - Tran, Khanh Bao
AU - Unnikrishnan, Bhaskaran
AU - Violante, Francesco S.
AU - Vu, Giang Thu
AU - Yamada, Tomohide
AU - Yaya, Sanni
AU - Yip, Paul
AU - Yonemoto, Naohiro
AU - Yu, Chuanhua
AU - Yu, Yong
AU - Zamanian, Maryam
AU - Zhang, Yunquan
AU - Zhang, Zhi Jiang
AU - Ziapour, Arash
AU - Hay, Simon I.
AU - LBD 2019 Neglected Tropical Diseases Collaborators
N1 - Funding Information: M Ausloos reports grants or contracts from the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI (research grant (oct 2018-sep 2022); role: team leader (Bucharest University of Economic Studies); grant title “Understanding and modelling time-space patterns of psychology-related inequalities and polarization”), outside the submitted work. T Bärnighausen reports research grants from the European Union (Horizon 2020 and EIT Health), German Research Foundation (DFG), US National Institutes of Health, German Ministry of Education and Research, Alexander von Humboldt Foundation, Else-Kröner-Fresenius-Foundation, Wellcome Trust, Bill & Melinda Gates Foundation, KfW, UNAIDS, and WHO; consulting fees from KfW for the OSCAR initiative in Vietnam; participation on a Data Safety Monitoring Board or Advisory Board with NIH-funded study “Healthy Options” (PIs: Smith Fawzi, Kaaya), Chair, Data Safety and Monitoring Board (DSMB), German National Committee on the “Future of Public Health Research and Education”, Chair of the scientific advisory board to the EDCTP Evaluation, Member of the UNAIDS Evaluation Expert Advisory Committee, National Institutes of Health Study Section Member on Population and Public Health Approaches to HIV/AIDS (PPAH), US National Academies of Sciences, Engineering, and Medicine’s Committee for the “Evaluation of Human Resources for Health in the Republic of Rwanda under the President’s Emergency Plan for AIDS Relief (PEPFAR)”, University of Pennsylvania (UPenn) Population Aging Research Center (PARC) External Advisory Board Member; leadership role of the Global Health Hub Germany (initiated by the German Ministry of Health) as a co-chair; all outside the submitted work. R C Franklin reports a leadership or fiduciary role in board, society, committee or advocacy group, paid or unpaid, with the Australasian College of Tropical Medicine as the Honorary Treasurer and Vice President; outside the submitted work. C Herteliu and A Pana report grants or contracts from Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084 (oct 2018-sep 2022) “Understanding and modelling time-space patterns of psychology-related inequalities and polarization” and project number PN-III-P2-2.1-SOL-2020-2-0351 (jun 2020-oct 2020) “Approaches within public health management in the context of COVID-19 pandemic”, all outside the submitted work. J S Ji reports consulting fees paid directly from The World Bank Group; honoraria from the Chinese Preventive Medicine Association and China Center for Disease Control and Prevention National Institute of Environmental Health Science, outside the submitted work. J Jozwiak reports payments from Teva Pharmaceuticals, Amgen, Synexus, Boehringer Ingelheim, ALAB laboratoria, and Zentiva as personal fees outside the submitted work. A Sheikh reports a research grant to their institutions from Health Data Research UK outside the submitted work. J A Singh reports consulting fees from Crealta/Horizon, Medisys, Fidia, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, MedIQ, Jupiter Life Science, UBM LLC, Trio Health, Medscape, WebMD, and Practice Point communications; and the National Institutes of Health and the American College of Rheumatology; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Simply Speaking; support for attending meetings and/or travel from OMERACT, an international organization that develops measures for clinical trials and receives arm’s length funding from 12 pharmaceutical companies, when traveling to OMERACT meetings; participation on a Data Safety Monitoring Board or Advisory Board as a member of the FDA Arthritis Advisory Committee; leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid, with OMERACT as a member of the steering committee, with the Veterans Affairs Rheumatology Field Advisory Committee as a member, and with the UAB Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis as a director and editor; stock or stock options in TPT Global Tech, Vaxart pharmaceuticals, Atyu Biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics, Inc., Seres Therapeutics and Charlotte’s Web Holdings Inc. and previously owned stock options in Amarin, Viking, and Moderna pharmaceuticals; all outside the submitted work. W A Stolk reports grants or contracts from the Bill and Melinda Gates Foundation (BMGF) as an active member of the NTD Modelling Consortium (grant number OPP1184344); consulting fees from Mectizan Donation Programme as a member of the Mectizan Expert Committee (MEC) in the form of a small honorarium for participating in MEC meetings; all outside the submitted work. All other authors declare that they have no competing interests. Funding Information: This work was primarily supported by a grant from the Bill & Melinda Gates Foundation OPP1132415. The funder had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to study data and had final responsibility for the decision to submit for publication. Funding Information: Data accessed via the ESPEN portal belong to the Ministries of Health and we would like to acknowledge the national onchocerciasis control and elimination programs for making these data available. F Carvalho FCT acknowledges Fundação para a Ciência e a Tecnologia, I.P., in the scope of the project UIDP/04378/2020 and UIDB/04378/2020 of the Research Unit on Applied Molecular Biosciences - UCIBIO and the project LA/P/0140/2020 of the Associate Laboratory Institute for Health and Bioeconomy - i4HB; FCT/MCTES (Ministério da Ciência, Tecnologia e Ensino Superior) through the project UIDB/50006/2020M Ausloos, A Pana and C Herteliu are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P4-ID-PCCF-2016-0084. C Herteliu and A Pana are partially supported by a grant of the Romanian National Authority for Scientific Research and Innovation, CNDS-UEFISCDI, project number PN-III-P2-2.1-SOL-2020-2-0351. A M Samy acknowledges the support from the Egyptian Fulbright Mission program and Ain Shams University. A I Ribeiro was supported by National Funds through FCT, under the program of Stimulus of Scientific Employment “Individual Support” within the contract CEECIND/02386/2018. A Sheikh acknowledges the support of Health Data Research UK. M N Khan acknowledges the support of Jatiya Kabi Kazi Nazrul Islam University, Mymensingh, Bangladesh. B Unnikrishnan acknowledges Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal. K Deribe is supported by the Wellcome Trust [grant number 201900/Z/16/Z] as part of his International Intermediate Fellowship. O Adetokunboh acknowledges the South African Department of Science and Innovation, and National Research Foundation. Y J Kim acknowledges support by the Research Management Centre, Xiamen University Malaysia [No. XMUMRF/2020-C6/ITCM/0004]. T Bärnighausen was supported by the Alexander von Humboldt Foundation through the Alexander von Humboldt Professor award, funded by the German Federal Ministry of Education and Research. W Stolk gratefully acknowledges funding from the NTD Modelling Consortium by the Bill & Melinda Gates Foundation (grant number OPP1184344). Publisher Copyright: © 2022, The Author(s).
PY - 2022/9/7
Y1 - 2022/9/7
N2 - Background: Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission. Methods: A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000–2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates of all-age 2000–2018 onchocerciasis infection prevalence at the 5 × 5-km resolution as well as aggregations to the national level, along with corresponding estimates of the uncertainty in these predictions. Results: As of 2018, the prevalence of onchocerciasis infection continues to be concentrated across central and western Africa, with the highest mean estimates at the national level in Ghana (12.2%, 95% uncertainty interval [UI] 5.0–22.7). Mean estimates exceed 5% infection prevalence at the national level for Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Guinea-Bissau, Sierra Leone, and South Sudan. Conclusions: Our analysis suggests that onchocerciasis infection has declined over the last two decades throughout western and central Africa. Focal areas of Angola, Cameroon, the Democratic Republic of the Congo, Ethiopia, Ghana, Guinea, Mali, Nigeria, South Sudan, and Uganda continue to have mean microfiladermia prevalence estimates exceeding 25%. At and above this level, the continuation or initiation of mass drug administration with ivermectin is supported. If national programs aim to eliminate onchocerciasis infection, additional surveillance or supervision of areas of predicted high prevalence would be warranted to ensure sufficiently high coverage of program interventions.
AB - Background: Onchocerciasis is a disease caused by infection with Onchocerca volvulus, which is transmitted to humans via the bite of several species of black fly, and is responsible for permanent blindness or vision loss, as well as severe skin disease. Predominantly endemic in parts of Africa and Yemen, preventive chemotherapy with mass drug administration of ivermectin is the primary intervention recommended for the elimination of its transmission. Methods: A dataset of 18,116 geo-referenced prevalence survey datapoints was used to model annual 2000–2018 infection prevalence in Africa and Yemen. Using Bayesian model-based geostatistics, we generated spatially continuous estimates of all-age 2000–2018 onchocerciasis infection prevalence at the 5 × 5-km resolution as well as aggregations to the national level, along with corresponding estimates of the uncertainty in these predictions. Results: As of 2018, the prevalence of onchocerciasis infection continues to be concentrated across central and western Africa, with the highest mean estimates at the national level in Ghana (12.2%, 95% uncertainty interval [UI] 5.0–22.7). Mean estimates exceed 5% infection prevalence at the national level for Cameroon, Central African Republic, Democratic Republic of the Congo (DRC), Guinea-Bissau, Sierra Leone, and South Sudan. Conclusions: Our analysis suggests that onchocerciasis infection has declined over the last two decades throughout western and central Africa. Focal areas of Angola, Cameroon, the Democratic Republic of the Congo, Ethiopia, Ghana, Guinea, Mali, Nigeria, South Sudan, and Uganda continue to have mean microfiladermia prevalence estimates exceeding 25%. At and above this level, the continuation or initiation of mass drug administration with ivermectin is supported. If national programs aim to eliminate onchocerciasis infection, additional surveillance or supervision of areas of predicted high prevalence would be warranted to ensure sufficiently high coverage of program interventions.
KW - Geospatial model
KW - Neglected tropical diseases
KW - Onchocerciasis
UR - http://www.scopus.com/inward/record.url?scp=85137312681&partnerID=8YFLogxK
U2 - 10.1186/s12916-022-02486-y
DO - 10.1186/s12916-022-02486-y
M3 - Article
C2 - 36068517
AN - SCOPUS:85137312681
SN - 1741-7015
VL - 20
JO - BMC Medicine
JF - BMC Medicine
IS - 1
M1 - 293
ER -